Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prothrombin index decrease: a useful and reliable marker of extensive fibrosis?

Jean-Francois Cadranel1, Philippe Mathurin

  • 1Unité d'Hépatologie, Hôpital Laënnec, BP 72, 60109 Creil Cedex, France. jfrancois.cadranel@ch-creil.fr

European Journal of Gastroenterology & Hepatology
|October 4, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

JHEP reports : innovation in hepatology·2026
Same author

Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort.

JHEP reports : innovation in hepatology·2026
Same author

Updates in clinical science: Alcohol-related hepatitis.

Journal of hepatology·2026
Same author

Trends in mortality and years of life lost among patients with cirrhosis and hepatocellular carcinoma in France, 2011-2023: a nationwide retrospective population-based study.

The Lancet regional health. Europe·2026
Same author

Implementing sustainable liver health in Europe: a second EASL-Lancet Commission.

Lancet (London, England)·2026
Same author

Success of transition to adult care in patients with pediatric-onset chronic liver disease.

Journal of pediatric gastroenterology and nutrition·2026
Same journal

Comment on 'Associations between 12 insulin resistance surrogates with metabolic dysfunction-associated steatotic liver disease risk and all-cause mortality: data from the National Health and Nutrition Examination Survey III (1988-1994)'.

European journal of gastroenterology & hepatology·2026
Same journal

Alarm symptoms at diagnosis of coeliac disease and long-term outcomes.

European journal of gastroenterology & hepatology·2026
Same journal

Artificial intelligence-integrated nanotherapeutics for rare Peutz-Jeghers syndrome hamartoma-induced obstructions: latest clearance strategies.

European journal of gastroenterology & hepatology·2026
Same journal

'Presence of alarm symptoms at coeliac disease diagnosis is not associated with poorer long-term treatment outcomes' [Letter].

European journal of gastroenterology & hepatology·2026
Same journal

Atrial fibrillation in patients with alcohol-associated hepatitis leads to increased mortality.

European journal of gastroenterology & hepatology·2026
Same journal

Association between albumin-bilirubin score, model for end-stage liver disease score, platelet-albumin-bilirubin score, and acute-on-chronic liver failure complications: a cross-sectional study in a Chinese population.

European journal of gastroenterology & hepatology·2026
See all related articles

Extensive liver fibrosis diagnosis needs reliable non-invasive methods. The prothrombin index shows promise as a cost-effective serum marker for detecting advanced liver fibrosis.

Area of Science:

  • Hepatology
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • Histological analysis for liver fibrosis is the gold standard but has limitations, including false-negative rates and invasiveness.
  • Liver biopsy, though definitive, carries risks and requires repeated procedures for monitoring chronic liver diseases like viral hepatitis.
  • There is a clinical need for accurate, non-invasive methods to assess the extent of liver fibrosis.

Discussion:

  • This article reviews advancements in non-invasive serum markers for predicting liver fibrosis.
  • The prothrombin index is highlighted as a particularly promising marker.
  • Its reliability and cost-effectiveness make it suitable for widespread clinical application.

Key Insights:

  • Non-invasive serum markers can overcome the limitations of liver biopsy in diagnosing and monitoring liver fibrosis.

Related Experiment Videos

  • The prothrombin index demonstrates potential as a dependable and affordable diagnostic tool.
  • Accurate fibrosis assessment is crucial for managing chronic liver conditions.

    • Outlook:

    • Further validation of the prothrombin index in diverse patient populations is warranted.
    • Development of non-invasive markers will improve patient outcomes and reduce healthcare costs.
    • Integration of serum markers into routine clinical practice could transform liver disease management.